An Open Question: Is It Rational to Inhibit the mTor-Dependent Pathway as COVID-19 Therapy?
mTOR, Everolimus, immune regulation, hyper-activation, COVID-19
Giuseppe Terrazzano, Angela Giovazzino, Valentina Rubino, Anna Teresa Palatucci, Giuseppina Ruggiero, Flavia Carriero